Back To The Power Alley: Guggenheim Securities Slightly Trims Merck's One Year NYSE Price Target -- But Still Forecasts... ~30% Upsides, From This Morning.

Let us try to find some smallish sense of normalcy, in this most chaotic of moments. I do trust that Kamala will offer a gracious unifying speech this evening, despite the way her opponent has belittled and demeaned her -- as a woman.

To that end, we would note that the "Gugg" is pretty astute -- and while the slight dip in growth rates for the China sales of Gardasil are not insubstantial, pembrolizumab sales increases are very likely to fill any dip that the HPV vaccines might post, by year end 2025. So yes, with Merck at just over $100 a share this afternoon -- and thus a "Buy" rating, with a 30% upside is still pretty outstanding, for a 12 month return. Here's that story, from this "morning after's" [hangover]:

. . .Guggenheim lowered the firm’s price target on Merck to $130 from $137 and keeps a Buy rating on the shares. While noting shares are down about 2.6% since the company reported Q3 earnings last week, with much of the focus remaining on Gardasil sales in the quarter that were well below expectations, the firm adds that it was “encouraged” by Keytruda’s continued strength and Winrevair’s uptake in its first full quarter on the market. . . .

Now you know. Take your time. Breathe deeply, and focus on all the good things. . . that still are. . . true.

नमस्ते